Literature DB >> 19962860

Evidence of gray matter reduction and dysfunction in chromosome 22q11.2 deletion syndrome.

Vandana Shashi1, Thomas R Kwapil, Jessica Kaczorowski, Margaret N Berry, Cesar S Santos, Timothy D Howard, Dhruman Goradia, Konasale Prasad, Diwadkar Vaibhav, Rajaprabhakaran Rajarethinam, Edward Spence, Matcheri S Keshavan.   

Abstract

Chromosome 22q11.2 deletion syndrome (22q11DS) is associated with cognitive deficits and morphometric brain abnormalities in childhood and a markedly elevated risk of schizophrenia in adolescence/early adulthood. Determining the relationship between neurocognition and neuroimaging findings would yield crucial information about childhood neurodevelopment and provide a basis for the study of the trajectory that occurs on the pathway to psychosis. We compared morphometric brain findings between non-psychotic children with 22q11DS (n = 22) and healthy controls (n = 16), and examined the association between neurocognitive functioning and morphometric brain findings. Volumetric regional gray matter differences between the 22q11DS and control subjects were measured, and correlations of the regional gray matter volumes and neurocognition were performed. Children with 22q11DS demonstrated reductions in gray matter in several brain regions, chiefly the frontal cortices, the cingulate gyrus and the cerebellum. The volumetric reductions in these salient areas were associated with poor performance in sustained attention, executive function and verbal memory; however, the relation of brain volume with cognitive performance did not differ between the patient and control groups. Thus, children with 22q11DS demonstrate gray matter reductions in multiple brain regions that are thought to be relevant to schizophrenia. The correlation of these volumetric reductions with poor neurocognition indicates that these brain regions may mediate higher neurocognitive functions implicated in schizophrenia.

Entities:  

Mesh:

Year:  2010        PMID: 19962860      PMCID: PMC2794985          DOI: 10.1016/j.pscychresns.2009.07.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  69 in total

Review 1.  Misunderstanding analysis of covariance.

Authors:  G A Miller; J P Chapman
Journal:  J Abnorm Psychol       Date:  2001-02

Review 2.  Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms.

Authors:  N C Andreasen; P Nopoulos; D S O'Leary; D D Miller; T Wassink; M Flaum
Journal:  Biol Psychiatry       Date:  1999-10-01       Impact factor: 13.382

3.  Regional cortical white matter reductions in velocardiofacial syndrome: a volumetric MRI analysis.

Authors:  W R Kates; C P Burnette; E W Jabs; J Rutberg; A M Murphy; M Grados; M Geraghty; W E Kaufmann; G D Pearlson
Journal:  Biol Psychiatry       Date:  2001-04-15       Impact factor: 13.382

4.  Brain and behaviour in children with 22q11.2 deletion syndrome: a volumetric and voxel-based morphometry MRI study.

Authors:  Linda E Campbell; Eileen Daly; Fiona Toal; Angela Stevens; Rayna Azuma; Marco Catani; Virginia Ng; Therese van Amelsvoort; Xavier Chitnis; William Cutter; Declan G M Murphy; Kieran C Murphy
Journal:  Brain       Date:  2006-03-28       Impact factor: 13.501

5.  Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives.

Authors:  A E Pulver; G Nestadt; R Goldberg; R J Shprintzen; M Lamacz; P S Wolyniec; B Morrow; M Karayiorgou; S E Antonarakis; D Housman
Journal:  J Nerv Ment Dis       Date:  1994-08       Impact factor: 2.254

6.  Velo-cardio-facial syndrome: language and psychological profiles.

Authors:  K J Golding-Kushner; G Weller; R J Shprintzen
Journal:  J Craniofac Genet Dev Biol       Date:  1985

7.  Prefrontal-thalamic-cerebellar gray matter networks and executive functioning in schizophrenia.

Authors:  Nicolas Rüsch; Ilaria Spoletini; Marko Wilke; Pietro Bria; Margherita Di Paola; Fulvia Di Iulio; Giovanni Martinotti; Carlo Caltagirone; Gianfranco Spalletta
Journal:  Schizophr Res       Date:  2007-03-26       Impact factor: 4.939

8.  Abnormal patterns of cortical gyrification in velo-cardio-facial syndrome (deletion 22q11.2): an MRI study.

Authors:  Marie Schaer; J Eric Schmitt; Bronwyn Glaser; François Lazeyras; Jacqueline Delavelle; Stephan Eliez
Journal:  Psychiatry Res       Date:  2006-01-04       Impact factor: 3.222

9.  Structural brain abnormalities associated with deletion at chromosome 22q11: quantitative neuroimaging study of adults with velo-cardio-facial syndrome.

Authors:  T van Amelsvoort; E Daly; D Robertson; J Suckling; V Ng; H Critchley; M J Owen; J Henry; K C Murphy; D G Murphy
Journal:  Br J Psychiatry       Date:  2001-05       Impact factor: 9.319

10.  Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder?

Authors:  D F Papolos; G L Faedda; S Veit; R Goldberg; B Morrow; R Kucherlapati; R J Shprintzen
Journal:  Am J Psychiatry       Date:  1996-12       Impact factor: 18.112

View more
  23 in total

Review 1.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

Review 2.  Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome.

Authors:  Nicole Philip; Anne Bassett
Journal:  Behav Genet       Date:  2011-05-15       Impact factor: 2.805

3.  Attentional functioning in individuals with 22q11 deletion syndrome: insight from ERPs.

Authors:  Daniela Mannarelli; Caterina Pauletti; Tommaso Accinni; Luca Carlone; Marianna Frascarelli; Guido Maria Lattanzi; Antonio Currà; Francesco Fattapposta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-08       Impact factor: 3.575

4.  Frontal Hypoactivation During a Working Memory Task in Children With 22q11 Deletion Syndrome.

Authors:  Waverly Harrell; Ling Zou; Zoe Englander; Stephen R Hooper; Matcheri S Keshavan; Allen Song; Vandana Shashi
Journal:  J Child Neurol       Date:  2016-10-04       Impact factor: 1.987

5.  Children with chromosome 22q11.2 deletion syndrome exhibit impaired spatial working memory.

Authors:  Ling M Wong; Tracy Riggins; Danielle Harvey; Margarita Cabaral; Tony J Simon
Journal:  Am J Intellect Dev Disabil       Date:  2014-03

6.  Atypical developmental trajectory of functionally significant cortical areas in children with chromosome 22q11.2 deletion syndrome.

Authors:  Siddharth Srivastava; Michael H Buonocore; Tony J Simon
Journal:  Hum Brain Mapp       Date:  2011-03-17       Impact factor: 5.038

Review 7.  Modeling a model: Mouse genetics, 22q11.2 Deletion Syndrome, and disorders of cortical circuit development.

Authors:  Daniel W Meechan; Thomas M Maynard; Eric S Tucker; Alejandra Fernandez; Beverly A Karpinski; Lawrence A Rothblat; Anthony-S LaMantia
Journal:  Prog Neurobiol       Date:  2015-04-09       Impact factor: 11.685

8.  Exome Sequence Data From Multigenerational Families Implicate AMPA Receptor Trafficking in Neurocognitive Impairment and Schizophrenia Risk.

Authors:  Mark Z Kos; Melanie A Carless; Juan Peralta; August Blackburn; Marcio Almeida; David Roalf; Michael F Pogue-Geile; Konasale Prasad; Ruben C Gur; Vishwajit Nimgaonkar; Joanne E Curran; Ravi Duggirala; David C Glahn; John Blangero; Raquel E Gur; Laura Almasy
Journal:  Schizophr Bull       Date:  2015-09-24       Impact factor: 9.306

9.  Cognitive ability is associated with altered medial frontal cortical circuits in the LgDel mouse model of 22q11.2DS.

Authors:  D W Meechan; H L H Rutz; M S Fralish; T M Maynard; L A Rothblat; A-S LaMantia
Journal:  Cereb Cortex       Date:  2013-11-11       Impact factor: 5.357

10.  Secondary psychoses: an update.

Authors:  Matcheri S Keshavan; Yoshio Kaneko
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.